Compare REGN & FDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | FDX |
|---|---|---|
| Founded | 1988 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4B | 85.7B |
| IPO Year | 1995 | 1997 |
| Metric | REGN | FDX |
|---|---|---|
| Price | $786.23 | $383.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 21 |
| Target Price | ★ $815.04 | $335.33 |
| AVG Volume (30 Days) | 657.5K | ★ 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 0.49% | ★ 1.52% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 41.48 | 7.50 |
| Revenue | $5,872,227,000.00 | ★ $65,450,000,000.00 |
| Revenue This Year | $11.69 | $6.46 |
| Revenue Next Year | $10.12 | $4.12 |
| P/E Ratio | ★ $18.54 | $50.99 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $476.49 | $194.30 |
| 52 Week High | $821.11 | $392.86 |
| Indicator | REGN | FDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.95 | 70.13 |
| Support Level | $737.04 | $220.40 |
| Resistance Level | $818.06 | N/A |
| Average True Range (ATR) | 21.81 | 9.16 |
| MACD | -1.05 | -2.13 |
| Stochastic Oscillator | 55.37 | 71.40 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In fiscal 2025, the firm's Federal Express segment-which houses the core package delivery operations-made up 86% of total revenue, with 10% coming from FedEx Freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.